قالب وردپرس درنا توس
Home / Business / Rep. Ocasio-Cortez beats Gilead over the HIV drug prices

Rep. Ocasio-Cortez beats Gilead over the HIV drug prices



Rep. Alexandria Ocasio-Cortez, DN.Y., did not hold back Thursday's question to CEO who makes Truvada high cost for the drug used to prevent pre-exposure HIV or PrEP.

"The list price is almost $ 2000 in the US. Why is it $ 8 in Australia?" Ocasio-Cortez asked the CEO of Gilead Sciences, Daniel O & # 39; Day, after he noted that the company had made $ 3 billion in sales of the one-time pill in 2018.

Day replied, "Truvada still has patent protection in the United States, and in the rest of the world, it is generic. "He noted that, as announced last week, the drug is generally available in the United States in September 2020.

" There is no reason this should be $ 2,000 a month , "Ocasio-Cortez, who has pushed for the hearing before the House Committee for Supervision and Reform.

Former MD Martin Shkreli

16 PHOTO

Former drug consultant Martin Shkreli

        

        

] View Gallery

Martin Shkreli, former CEO of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, resigns after a hearing at the US Federal Court in Brooklyn, New York, USA, June 26, 2017. REUTERS / Lucas Jackson [19659011] Martin Shkreli, CEO of Turing Pharmaceuticals LLC, center and lawyer Evan Greebel, left, left the federal court in New York, USA, on Thursday, December 17, 2015. Shkreli was arrested on allegedly valuable fraud linked to Retrophin Inc., a biotech company founded in 2011. Greebel is accused of conspiring with Shkreli in part of the scheme. Photographer: Peter Foley / Bloomberg via Getty Images

Martin Shkreli, CEO of Turing Pharmaceuticals LLC, derives federal court in New York, United States, Thursday, December 17, 2015. Shkreli was arrested on allegedly valuable fraud related to Retrophin Inc. a biotechnology firm he founded in 2011. Photographer: Peter Foley / Bloomberg via Getty Images

Martin Shkreli, chief investor in MSMB Capital Management, is holding a photo in his office in New York, USA, Wednesday, August 10, 2011. MSMB made an undesirable $ 378 million takeover bid to Amag Pharmaceuticals Inc. and said it would mess up drug makers' top management if successful. Photographer: Paul Taggart / Bloomberg via Getty Images *** Local message ** Martin Shkreli

Martin Shkreli, chief investment director of MSMB Capital Management, works at a computer in his office in New York, USA, on Wednesday, August 10, 2011. MSMB made an undesirable bid of over $ 378 million for Amag Pharmaceuticals Inc. and said that It will burn the drugmaker top management if successful. Photographer: Paul Taggart / Bloomberg via Getty Images *** Local message ** Martin Shkreli

Martin Shkreli, chief investment in MSMB Capital Management, sits behind a chess board in New York, USA, Wednesday, August 10, 2011. MSMB did a $ 378 million unwanted takeover bid for Amag Pharmaceuticals Inc. and said it will mess up drug makers' top management if successful. Martin Shkreli (L), former CEO of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, comes to a hearing at the US Federal Court in Brooklyn, New York, USA October 14, 2016. REUTERS / Lucas Jackson

Martin Shkreli, former CEO in Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, resign after a hearing at the US Federal Court in Brooklyn, New York, USA, April 26, 2017. REUTERS / Brendan McDermid

Martin Shkreli (C), former CEO of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc arrives for a hearing at the US Federal Court in Brooklyn, New York, USA October 14, 2016. REUTERS / Lucas Jackson

Martin Shkreli (C), former CEO of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, arrives at US Federal Court in New York, USA, June 6, 2016. REUTERS / Lucas Jackson [19659020] Former drug forces Martin Shkreli leaving the US Federal Courthouse in Brookly n-borough in New York February 3, 2016. REUTERS / Brendan McDermid

Martin Shkreli (top R), former CEO of Turing Pharmaceuticals LLC, arrives before a house Reuters / Joshua Roberts

Martin Shkreli, former CEO in Turing Pharmaceuticals AG, on the right, ends the federal trial of "Prescription Pharmaceutical Market Monitoring" on Capitol Hill, Washington, February 4, 2016. His lawyer Benjamin Brafman in the Brooklyn New York City, Thursday, June 29, 2017. Shkreli is accused to construct separate scams related to his control over two hedge funds he ran as well as "Retrophin Inc., a pharmaceutical company He founded in 2011. Photographer: Peter Foley / Bloomberg via Getty Images

Martin Shkreli (C) , CEO of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs the United States Fe Deral Court after an arraignment after being charged in a federal charge filed in Brooklyn linked to his leadership of the hedge fund MSMB Capital Management and biopharmaceutical company Retrophin Inc. in New York on December 17, 2015. REUTERS / Lucas Jackson

Bloomberg Best of Year 2016: Martin Shkreli, former CEO of Turing Pharmaceuticals LLC, responded under a house committee for oversight and government reform consultation on prescription drug prices in Washington, DC, USA, Thursday, February 4, 2016. Shkreli, who is no longer with Turing and is facing federal fraud charges not related to drugmaker, refused to comment on the committee. "On the advice of counsel, I invoke my fifth change," Shkreli said. Photographer: Pete Marovich / Bloomberg via Getty Images

Martin Shkreli, former CEO of Turing Pharmaceuticals LLC, smiles at a House Committee for Monitoring and Government Reform Consultation on Prescription Drug Prices in Washington, DC, USA, Thursday, February 4, 2016 Shkreli, who is no longer with Turing and is facing federal fraud charges not related to drugmaker, refused to comment on the committee. "On the advice of counsel, I invoke my fifth change," Shkreli said. Photographer: Pete Marovich / Bloomberg via Getty Images




HIDE CAPTION

SHOW CAPTION

Ocasio-Cortez also claimed, as alleged by activists and academics, that Truvada's use as an HIV preventive pill was discovered by the US government.

"We the public, we the people, developed this drug, we paid for this drug, we lead and we all developed the ground patents to create PrEP, and then the patent has been privatized despite the patent being owned by the public, who refused to enforce it, "Ocasio-Cortez said.

In prepared remarks, the Day denied accusations such as Centers for Disease Control and Prevention, part of the Department of Health and Human Services, own the PrEP patent. "Every Gilead employee is proud to have invented Truvada, a drug that can both treat and prevent HIV," he said.

"Our well-supported view is that the US government does not have valid patents on the use of Truvada for pre-exposure prophylaxis, nor does it contain a patent for Truvada itself," added O & # 39; Day.

The hearing came as activists have pushed up pressure on Gilead, a company that commercializes and produces a variety of treatments and cures for chronic diseases.

Members of the PrEP4All collaboration, a group of activists who pushed for broad PrEP access, and legal experts filed a complaint action on Tuesday claiming that the nation's largest HIV drug manufacturers, including Gilead, for years conspired to keep cheaper generic component drugs out of popular "combination pills" that make treating HIV as simple as taking a pill a day.


Source link